IPO registrations (S-1, F-1) · Registrants
MICROMET, INC.
- SEC CIK
- 1131907 · filings on EDGAR ↗
- Name on the registration
- CANCERVAX CORP
- Former names
- CANCERVAX CORP (2002–2006)
- Registration
- Form S-1, first filed 2003-08-14, last 2003-10-24; 1 initial registration, 4 amendments
- Outcome
- Final prospectus filed 2003-10-30
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 9201 CORPORATE BOULEVARD,, SUITE 400,, Rockville,, MD 20850
- EIN
- 52-2243564
- EDGAR entity type
- operating
- Insiders and CEO pay
- MICROMET, INC. on the corporate pages
Offering terms
- Proposed price range
- $12.00–$14.00 per share (S-1/A filed 2003-10-24)
- Final price
- $12.00 per share, within the range (424B4 filed 2003-10-30, an initial public offering)
- Shares sold
- 6,000,000
- Gross proceeds
- $72,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CNVX
- Lead underwriters
- Lehman Brothers; Citigroup (1,120,000 shares); Thomas Weisel Partners (1,120,000 shares); Piper Sandler (1,120,000 shares)
- Syndicate
- Legg Mason (100,000); Cowen (100,000); Roth Capital Partners (50,000); ThinkEquity (50,000)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: AMGEN ROCKVILLE, INC. EXACT (EIN (EXACT))
- Form D issuer: MICROMET, INC. EXACT (CIK (EXACT))
- SEC filer: CANCERVAX CORP EXACT (CIK (EXACT))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2003-08-14 | S-1 | S-1 (registration) | CANCERVAX CORP | 0000936392-03-001171 ↗ |
| 2003-09-03 | S-1/A | S-1/A (amendment) | CANCERVAX CORP | 0000936392-03-001230 ↗ |
| 2003-09-16 | S-1/A | S-1/A (amendment) | CANCERVAX CORP | 0000936392-03-001277 ↗ |
| 2003-10-10 | S-1/A | S-1/A (amendment) | CANCERVAX CORP | 0000936392-03-001379 ↗ |
| 2003-10-24 | S-1/A | S-1/A (amendment) | CANCERVAX CORP | 0000936392-03-001431 ↗ |
| 2003-10-30 | 424B4 | 424B4 (final prospectus) | CANCERVAX CORP | 0000892569-03-002445 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2003-10-24 | S-1/A | registration statement | $12.00–$14.00 | 6,000,000 | - | Nasdaq CNVX | 4 | primary document; range, price line, shares headline, proceeds computed, price outside the range dropped | document ↗ | |
| 2003-10-30 | 424B4 | final prospectus | $12.00 | 6,000,000 | $72,000,000 | Nasdaq CNVX | 8 | primary document; price sentence, shares headline, proceeds table, underwriting table 7 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| AKER HAZEL M | Officer | Sr. VP, General Counsel | 2 | 2006 | |
| GAMMON GUY | Officer | Vice President, Clinical | 2 | 2006 | |
| HALE DAVID F | Director; Director,Officer; DirectorOther | President and CEO | 24 | 2006–2012 | |
| LARUE WILLIAM R | Officer | Sr.VP and CFO | 2 | 2006 | |
| VAN EPPS DENNIS E | Officer | VP, Research | 2 | 2006 | |
| Baeuerle Patrick | Officer | SVP, Chief Scientific Officer; SVP & CSO; SVP, CSO; SVP R&D, CSO | 12 | 2006–2012 | |
| Berriman John E | Director | 10 | 2006–2012 | ||
| CARTER MICHAEL G | Director | 9 | 2006–2012 | ||
| Guille Andrew | TenPercentOwner | 1 | 2006 | ||
| Helyar Connie | TenPercentOwner | 7 | 2006–2009 | ||
| Hennecke Jens | Officer | SVP - Business Development; SVP Business Development; SVP, Business Development; SVP-Business Development; VP Business Development; VP, Business Development | 11 | 2006–2012 | |
| Itin Christian | Director,Officer; Officer | President and CEO; President & CEO; President, CEO | 11 | 2006–2012 | |
| Mirow Gregor | Officer | SVP, Operations | 2 | 2006 | |
| Omega Fund GP, Ltd. | TenPercentOwner | 2 | 2006–2007 | ||
| Omega Fund I, L.P. | TenPercentOwner | 2 | 2006–2007 | ||
| Omega Fund Management LTD | TenPercentOwner | 7 | 2006–2009 | ||
| PHILLIPS BARCLAY A | Director; Officer | SVP & CFO; SVP, CFO; SVP / Chief Financial Officer; SVP, Chief Financial Officer | 11 | 2006–2012 | |
| Reinhardt Carsten | Officer | Chief Medical Officer; SVP, Clinical Development; SVP & CMO | 8 | 2006–2009 | |
| SCHNEIDER PHILLIP M | Director | 2 | 2006–2007 | ||
| Sigma Holding LTD | TenPercentOwner | 7 | 2006–2009 | ||
| Stampacchia Otello | Director; Director,TenPercentOwner | 30 | 2006–2010 | ||
| BENJAMIN JERRY | Director; Director,TenPercentOwner | 11 | 2006–2010 | ||
| 31 GROUP PLC | TenPercentOwner | 1 | 2006 | ||
| ADVENT MANAGEMENT III L P | TenPercentOwner | 1 | 2006 | ||
| ADVENT PRIVATE EQUITY FUND III AFFILIATES | TenPercentOwner | 1 | 2006 | ||
| ADVENT PRIVATE EQUITY FUND III A LTD PARTNERSHIP | TenPercentOwner | 1 | 2006 | ||
| ADVENT PRIVATE EQUITY FUND III B LTD PARTNERSHIP | TenPercentOwner | 1 | 2006 | ||
| ADVENT PRIVATE EQUITY FUND III C LTD PARTNERSHIP | TenPercentOwner | 1 | 2006 | ||
| ADVENT PRIVATE EQUITY FUND III D LTD PARTNERSHIP | TenPercentOwner | 1 | 2006 | ||
| ADVENT PRIVATE EQUITY FUND III GMBH & CO KG | TenPercentOwner | 1 | 2006 | ||
| Johann Peter | Director | 14 | 2006–2012 | ||
| Alder Matthias | Officer | Sr.VP and General Counsel; SVP and General Counsel; SVP & GC; SVP, GC and Secretary; SVP & General Counsel; SVP, General Counsel; SVP, General Counsel & Sec. | 13 | 2006–2012 | |
| SCHNITTKER CHRISTOPHER P | Officer | Chief Financial Officer | 3 | 2006–2007 | |
| Luff John P | TenPercentOwner | 2 | 2006–2007 | ||
| Omega Fund III GP, L.P. | TenPercentOwner | 1 | 2007 | ||
| Omega Fund III G.P., Ltd. | TenPercentOwner | 1 | 2007 | ||
| Omega Fund III, L.P. | TenPercentOwner | 1 | 2007 | ||
| Reisenauer Mark L | Officer | SVP & CCO; SVP, CCO; SVP & Chief Commercial Officer; SVP, Chief Commercial Officer; SVP & Chief Commerical Officer | 11 | 2007–2011 | |
| SLATTERY JOSEPH P | Director | 9 | 2007–2012 | ||
| Zelm Donald A | Officer | Chief Financial Officer | 4 | 2007–2008 | |
| Alvarez-Masterton Sharon Rose | TenPercentOwner | 6 | 2008–2009 | ||
| Dhingra Kapil | Director | 5 | 2009–2011 | ||
| Fagerberg Jan | Officer | SVP and Chief Medical Officer; SVP, Chief Medical Officer; SVP & CMO | 5 | 2009–2012 | |
| GRAU ULRICH M | Officer | EVP and COO | 3 | 2011–2012 | |
| Lobacki Joseph M | Officer | SVP & Chief Commercial Officer | 3 | 2011–2012 | |
| AMGEN INC | TenPercentOwner | 3 | 2012 | ||
| Armstrong Acquisition Corp. | TenPercentOwner | 3 | 2012 | ||
| Bradway Robert A | Director | 1 | 2012 | ||
| Harper Sean E | Director | 1 | 2012 | ||
| MCNAMEE BRIAN M | Director | 1 | 2012 | ||
| Peacock Jonathan M | Director | 1 | 2012 | ||
| SCOTT DAVID J | Director | 1 | 2012 | ||
| SHARER KEVIN W | Director | 1 | 2012 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2012-03-12 | MICROMET, INC. | Biotechnology | $175,463,420 | $175,463,420 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | MICROMET, INC. | MD | Form D private offerings | CIK (EXACT) |
| SEC filer | MICROMET, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | AMGEN ROCKVILLE, INC. | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), MD first:
- OSIRIS THERAPEUTICS, INC. MD
- REGENXBIO Inc. MD
- ELUTIA INC. MD
- CHAMPIONS ONCOLOGY, INC. MD
- CASI Pharmaceuticals, Inc (DE) MD
- BioNTech SE 2M
- Immatics N.V. 2M
- CHEMOKINE THERAPEUTICS CORP A1
- Fusion Pharmaceuticals Inc. A6
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. AZ
In other datasets, the same topic (Health) in MD:
- Nonprofit: 4K FOR CANCER INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health